Skip to main content
NewslettersWatchlist

Helix Biopharm(HBP-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.2300
Day High0.2300
Open:0.2300
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Helix BioPharma: Bottom 25 Performing Stocks Year-to-Date on TSX (HBP)
Baystreet
Stocks in play: Helix BioPharma Corp.
The Globe and Mail
Helix BioPharma: Top 10 Undervalued Biotechnology Industry Stocks on TSE (HBP)
AccessWire
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.
AccessWire
Helix Biopharma Corp. Closes Private Placement
Baystreet
Stocks in play: Helix BioPharma Corp
AccessWire
Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results
AccessWire
Helix BioPharma Corp. Extends Period to Exercise Warrants
AccessWire
Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update
AccessWire
Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update
AccessWire
Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update
AccessWire
Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer
AccessWire
Helix BioPharma Corp. Announces Appointment of New Director
AccessWire
Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management
AccessWire
Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants
AccessWire
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results
AccessWire
Helix BioPharma Corp. Closes Private Placement
AccessWire
Helix Biopharma Corp. Provides Polish Subsidiary Divestiture Update
AccessWire
Helix BioPharma Corp. Provides Polish Subsidiary Divestiture Update
AccessWire
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
AccessWire
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
AccessWire
Helix BioPharma Corp. to Present at the SNN Network Virtual Conference
Globe NewsWire
Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results
AccessWire
Helix BioPharma Corp. to Present at Alpha Bronze Virtual Town Hall
Globe NewsWire
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results
Globe NewsWire
Proactive Virtual Event Showcases Four Rising Stars of the Life Sciences Industry
Globe NewsWire
Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum
Globe NewsWire
Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results
Globe NewsWire
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

Profile

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.